ANAVEX. NY TRÅD NY TRÅD over 100 % indrulning i Alzheimer!
-
Saa kom den første opjustering:
Anavex price target raised to $35 from $19 at Dawson James Dawson James analyst Jason Kolbert raised the firm's price target on Anavex to $35 from $19 and keeps a Buy rating on the shares after the company announced Phase 2 data that he said shows that its biomarker "appears to correlate with efficacy" in the Rett syndrome trial. He is increasing his view of the probability of success to 50% from 30% as he believes this data has implications across all the current trials, including Alzheimer's, Kolbert tells investors.
-
-
Anavex Anavex price target raised to $35 from $19 at Dawson James!
Lidt benzin på bålet - ringe i vandet!
Første af nok et øget og antal opgraderinger, samt tilgang af nye analytikere og deres kursmål.
For hvem med respekt for sig selv, kan udlade at dække et selskab, som måske kommer med det første virkelig gennembrud inden for CNS???
F.eks. burde Black Rock med deres 4.300.000 aktier melde ud, hvor de ser Anavex henne om et års tid.Tænker lige som Solsen, at det er de godt 80 % WT, som gælder alle mennesker og er bedst disponeret for en god effekt med 2-73, der henvises til. Mener dog også at der specifikt for RETT patienter var forskel på noget der hedder APOE gen - har dog ikke lige haft tid til at læse efter endnu.
-
når man kigger på sava og Annovis Bio, Inc. (ANVS), forståer jeg ikke helt hvorfor anavex ikke også er oppe på 100$ lige som de to andre.
hvis deres produkt er lige så godt eller bedre. er der nogle der kan forklarer det.
men ellers er det ikke så ringe end dag ,men det kunne værer bedre -
Ting tager tid. Men Anavex burde ligge med højere Mcap end dem du nævner.
Om de så er kontrakt værdisat er en anden sag.
Dagens data er efter min mening ikke belønnet nok. Men har sikkert noget med, at det er Rett indikationen.
Men kommer tilsvarende overbevisende data i PDD så er vi på $3bn Mcap.
-
Du kan ikke umiddelbart sammenligne kurserne på 2 forskellige aktier UDEN at tage antal cirkulerede aktier i betragtning. Hvis du vil sammenligne bør du i stedet se på selskabernes markedsværdier. Om det så giver et rigtigt billede af selskabernes reelle værdi, vil kun fremtiden kunne vise. Pt. mener "markedet" at SAVA' værdi er ca.
$ 3,5 mia, AVXL ca. $ 1,8 mia. og ANVS ca. $ 0,66 mia, se nedenstående oversigt
https://marketcomposite.com/topic?name=Alzheimer Treatment -
Anavex. Rigtig god analyse fra tidligere nævnte IHUB skribent.
Anavex får bevist sin precision tilgang. ( + 80% WT )
Markant og bred god respons i ældre piger, som ellers burde være næsten umuligt at se nogen forbedring i - og så endda på lav dosis i kun 7 uger.
Signifikant respons allerede efter 4 uger og effekten er endda tiltaget efter 7 uger.Dette tegner godt for forsøget med ældre piger på høj dosis senere i år - og endnu bedre for forsøget med yngre piger på høj dosis og 12 ugers varighed!
Resultater i extension forsøgene må blive virkelige gode.
Alt dette uden bivirkninger og med meget lille usikkerhed.
Sandsynliggør at precision tilgangen kan overføres til andre indikationer!
FDA kan ikke undgå at godkende 2-73 - måske allerede i år via. acc. godkendelse.
( Tror dog på en reaktion fra Australien inden )
Efter dette kan 2-73 i praksis udskrives i andre indikationer også - udløser desuden en voucher til en værdi af + 100 mill. $!Ganske få kender til RETT - men når Anavex inden 1. juli udgiver tilsvarende eller efter min overbevisning endnu bedre resultater i PDD, så får vi en helt anden markant respons i aktiekursen!
70 % af målepunkterne i PDD har sammenfald med Alzheimer - når dette går op for markedet for alvor, tør jeg ikke spå om kursen!Rigtig mange anede end ikke om eksistensen af Anavex for bare få uger siden.
Pusselspillet er næsten samlet nu - efter 6 lange år!
Anavex Life Sciences Corp (AVXL): Anavex 2-73-RS-001 Adult Low Dose Rett T...
MayoMobile: Anavex 2-73-RS-001 Adult Low Dose Rett Trial (U.S.) To precede commentary on Anavex 2-73-RS-001 data, I want to bring investor attention to a parti...
InvestorsHub (investorshub.advfn.com)
-
-
Anavex 50 mln USD ved emission i kurs $21
NEW YORK - June 22, 2021 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that it has entered into a definitive purchase agreement with Deep Track Capital for the issuance and sale of an aggregate of 2,380,953 shares of its common stock at a purchase price of $21.00 per share of common stock a registered direct offering. The registered direct offering is expected to close on or about June 24, 2021, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds from the offering are expected to be approximately $50 million before deducting placement agent fees and other offering expenses. Anavex currently intends to use the net proceeds from the offering for advancing its pipeline and for working capital and general corporate purposes.
The shares of common stock described above are being offered pursuant to Anavex's shelf registration statement on Form S-3 (File No. 333-232550) filed with the Securities and Exchange Commission (the "SEC") on July 3, 2019 and declared effective on July 15, 2019. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the shares of common stock being offered in the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: [email protected] or by telephone: (212) 856-5711.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex's lead drug candidate, ANAVEX
2-73 (blarcamesine), successfully completed a Phase 2a clinical trial for Alzheimer's disease and recently a Phase 2 proof-of-concept study in Parkinson's disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX2-73 for the treatment of Parkinson's disease. ANAVEX3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram and LinkedIn.Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: [email protected]Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461 -
Naa, Anavex sælger aktier for 50 mill $ til 21$ per stk!!
The gross proceeds from the offering are expected to be approximately $50 million before deducting placement agent fees and other offering expenses. Anavex currently intends to use the net proceeds from the offering for advancing its pipeline and for working capital and general corporate purposes.
Anavex Life Sciences Announces $50 Million Registered Direct Offering
NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that it has entered into a definitive purchase agreement with Deep Track Capital for the issuance a
Yahoo Finance (finance.yahoo.com)
Solsen kom mig i forkøbet
-
Det tegner ikke godt for de resultater vi venter på. Ikke med logisk sans that is. Æv, nu gik det lige så godt
-
Anavex henter 50 mill. $!
Anavex sælger ca. 2,4 mill. aktier til kurs 21 $!
Som jeg skrev tidligere, så håbede jeg på, at Anavex ville styrke deres finansielle situatinen ved nuværende kursniveau.
Vil de gå selv med RETT og måske og Parkinson, kræver det kapital.
Endvidere har de gode resultater i RETT åbnet muligheder for opstart i nye indikationer.SAVA hentede f.eks 200 mill. $ før jul, men har siden mangedoblet deres kurs.
ANVS hentede også lige 50 mill. $ og er siden steget en hel del.Denne gang har Anavex valgt, at hente pengene i en åben aktion, i stedet for et løbene salg af aktier - er sikker på, at de har forhåndskøbere til de 21 $.
Dem der køber til denne kurs forventer også sikkert, at kursen vil stige.Ser det som rettidig omhu og en styrkelse inden de næste afgørende skridt!
-
Tasso og solsen hvorfor så ikke vente til de sidste nyheder er offentliggjort? Jeg er udmærket klar over at de skal bruge penge, det er ikke det jeg anfægter. Æv
-
Anavex Rettelse SAVA og ANVS!
SAVA hentede i feb. 2021 200 mill. til kurs 49 $ - i dag har de kurs 90 $.
Cassava Sciences Announces Closing of $200 Million Registered Direct Offering
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The net proceeds of the offering are estimated to be approximately $189.7 million, after deducting placement agent fees and other estimated offering expenses. Cassava Sciences intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of simufilam, the Company’s lead drug candidate for the treatment of Alzheimer’s disease. The shares of common stock were offered by Cassava Sciences pursuant to an automatic "shelf" registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 10, 2021 and became effective immediately upon filing, and the base prospectus contained therein. The offering was made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to the shares of common stock being offered was filed with the SEC. Copies of the final prospectus supplement and accompanying base prospectus may be obtained on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at [email protected]. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction. About Cassava Sciences, Inc.Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For More Information Contact:Eric Schoen, Chief Financial OfficerCassava Sciences, [email protected](512) 501-2450 Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may include, without limitation, statements regarding (i) the estimated net proceeds and the use of proceeds of the registered direct offering, and (ii) the assumptions underlying or relating to any statement under clause (i). Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of those risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, unfavorable market conditions, occurrence of force majeure, the Company’s inability to obtain adequate financing to fund its operations and necessary to develop or enhance its products, the Company’s ability to conduct or complete clinical studies on expected timelines, the Company’s ability to demonstrate the specificity, safety, efficacy or potential health benefits of its product candidates, the severity and duration of health care precautions given the COVID-19 pandemic and unanticipated impacts of the pandemic on the Company’s business operations. These and other risk factors are identified and described in more detail in the prospectus supplement filed with the SEC in connection with the offering, including the Company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report on Form 10-Q, which are incorporated by reference in such prospectus supplement, and the other documents incorporated by reference in such prospectus supplement and Company’s other filings with the SEC. The Company does not undertake to update these forward-looking statements.
Yahoo Finance (finance.yahoo.com)
ANVS hentede i maj 2021 50 mill. til kurs 50 $ - i dag har de kurs 96 $.
https://finance.yahoo.com/news/annovis-bio-inc-announces-closing-155500148.html
Salget af de godt 2,4 mill. aktier svarer til en "udvanding" på kun ca. 3 % eller 0,75 $ ifht. kurs 25 $!
Men denne "udvanding" polstre jo kassen med gode 50 mill. $ - værdierne er jo ikke fjernet fra selskabet!
Mange andre sunde erhvervsselskaber tager jo også f.eks lån for at vokse/udvikle.
Genmab undlader f.eks. at udbetale store afkast til investorerne for at putte pengene i udvikling.Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
Berwyn, Pennsylvania--(Newsfile Corp. - May 27, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the closing of its underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $50.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and offering expenses. All of ...
Yahoo Finance (finance.yahoo.com)
Er overbevist om, at vi min. vil se tilsvarende kursudvikling som i SAVA og ANVS - så ro på - skidtet virker jo har vi lige set!
-
Anavex Rettelse SAVA og ANVS!
Ved ikke lige hvad der skete?
SAVA hentede i feb. 2021 200 mill. til kurs 49 $ - i dag har de kurs 90 $.
Cassava Sciences Announces Closing of $200 Million Registered Direct Offering
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The net proceeds of the offering are estimated to be approximately $189.7 million, after deducting placement agent fees and other estimated offering expenses. Cassava Sciences intends to use the net proceeds from this offering for working capital and general corporate purposes, including development of simufilam, the Company’s lead drug candidate for the treatment of Alzheimer’s disease. The shares of common stock were offered by Cassava Sciences pursuant to an automatic "shelf" registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 10, 2021 and became effective immediately upon filing, and the base prospectus contained therein. The offering was made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and accompanying base prospectus relating to the shares of common stock being offered was filed with the SEC. Copies of the final prospectus supplement and accompanying base prospectus may be obtained on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at [email protected]. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction. About Cassava Sciences, Inc.Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For More Information Contact:Eric Schoen, Chief Financial OfficerCassava Sciences, [email protected](512) 501-2450 Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may include, without limitation, statements regarding (i) the estimated net proceeds and the use of proceeds of the registered direct offering, and (ii) the assumptions underlying or relating to any statement under clause (i). Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of those risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, unfavorable market conditions, occurrence of force majeure, the Company’s inability to obtain adequate financing to fund its operations and necessary to develop or enhance its products, the Company’s ability to conduct or complete clinical studies on expected timelines, the Company’s ability to demonstrate the specificity, safety, efficacy or potential health benefits of its product candidates, the severity and duration of health care precautions given the COVID-19 pandemic and unanticipated impacts of the pandemic on the Company’s business operations. These and other risk factors are identified and described in more detail in the prospectus supplement filed with the SEC in connection with the offering, including the Company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report on Form 10-Q, which are incorporated by reference in such prospectus supplement, and the other documents incorporated by reference in such prospectus supplement and Company’s other filings with the SEC. The Company does not undertake to update these forward-looking statements.
Yahoo Finance (finance.yahoo.com)
ANVS hentede i maj 2021 50 mill. til kurs 50 $ - i dag har de kurs 96 $.
https://finance.yahoo.com/news/annovis-bio-inc-announces-closing-155500148.html
Salget af de godt 2,4 mill. aktier svarer til en "udvanding" på kun ca. 3 % eller 0,75 $ ifht. kurs 25 $!
Men denne "udvanding" polstre jo kassen med gode 50 mill. $ - værdierne er jo ikke fjernet fra selskabet!
Mange andre sunde erhvervsselskaber tager jo også f.eks lån for at vokse/udvikle.
Genmab undlader f.eks. at udbetale store afkast til investorerne for at putte pengene i udvikling.Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
Berwyn, Pennsylvania--(Newsfile Corp. - May 27, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the closing of its underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $50.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and offering expenses. All of ...
Yahoo Finance (finance.yahoo.com)
Er overbevist om, at vi min. vil se tilsvarende kursudvikling som i SAVA og ANVS - så ro på - skidtet virker jo har vi lige set!
-
Det er sådan at nye investorer gerne vil se der er mulighed for et godt afkast også på kort sige.
Så hvis alle de gode nyheder var brændt af var det jo ikke så interessant.
Men vi er trods alt i kurs 21
Jeg skal ikke afvise at der også er en vis rettidigt omhu i udvidelsen nu, da man jo ikke er 100% sikker på fremtiden i biotech og markedet generelt.
De Peer review artikler vi venter på tror jeg ikke man kan styre udgivelsestidspunktet af på kort sigt. Og jeg vil forvente, at man meget snart går i afsluttende forhandling med en stor partner på PDD - derfor skal man ikke være fattig, når man sidder ved det bord da det svækker forhandlingskraften
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind